| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PDMP | CTRPv2 | pan-cancer | AAC | -0.023 | 0.5 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.02 | 0.5 |
| mRNA | SCH-529074 | CTRPv2 | pan-cancer | AAC | -0.023 | 0.5 |
| mRNA | KIN001-236 | GDSC1000 | pan-cancer | AAC | 0.02 | 0.5 |
| mRNA | Fumonisin B1 | CTRPv2 | pan-cancer | AAC | -0.022 | 0.5 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.022 | 0.5 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | -0.02 | 0.5 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | 0.019 | 0.5 |
| mRNA | BRD-K50799972 | CTRPv2 | pan-cancer | AAC | 0.022 | 0.5 |
| mRNA | CHIR-99021 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.5 |